efficacy of the combination of fluticasone propionate and salmeterol in
Recommend Documents
in achieving guideline-defined asthma control in Asian patients. Methods: A post hoc ...... health status in both the Asian and non-Asian popula- tions studied in ..... healthy nonsmoking Asian-Americans and European-Americans. Am J Respir.
Apr 2, 2014 - 2014 Roche et al.; licensee BioMed Central Ltd. This is an Open Access article .... A minimum of 267 patients per group (i.e., included by.
Feb 19, 2006 - Peter Kardos, Marion Wencker, Thomas Glaab, and Claus Vogelmeier ..... sults of Donaldson and colleagues (38) and Spencer and Jones.
13M Drug Delivery Systems, St. Paul, MN 2Sylvana Research, San Antonio TX. 3 .... Based on the content results, the powd
Asthma and Allergy Physicians, Taunton, Massachusetts; Allergy and Asthma ... and Asthma Center, North Dartmouth, Massachusetts; Glaxo Wellcome Inc.,.
Apr 17, 2010 - Andras Koser1, Jan Westerman2, Sanjay Sharma3, Amanda Emmett3 and Glenn D. Crater*,3. 1Greenville ..... Celli BR, Macnee W. Standards for the diagnosis and treatment of ... Anzueto A, Ferguson GT, Feldman G, et al.
Antonio R. Anzueto1*, Konstantinos Kostikas2, Karen Mezzi2, Steven Shen3, ..... Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM,.
Mastocytosis is an abnormal accumulation of mast cells in the absence of an apparent cause [1, 2] . The skin is the most frequent site of involvement.
fluticasone propionate urinary TCM levels in ... where urinary TCM levels in the healthy subjects ..... randomisation schedule, I Fowler (Department of Biochemis-.
Nov 7, 1990 - rarricular, fluttcasone propionate is a fluorinated glucocorticoid, in which sys- ... Le propionate de fluticasone dans les maladies inflammatoires.
ABSTRACT: Exacerbations of chronic obstructive pulmonary disease (COPD) ... in Obstructive Lung Disease in Europe (ISOLDE) study in COPD showed a 26%.
Jan 24, 2012 - inhaled FP administered via nose-only aerosolized expos- ure alters innate ... SCIREQ, Montreal, QC, Canada) for eight successive days.
inhaled fluticasone propionate (FP) had an effect on lung function and on indices of ..... lidocaine spray, and the vocal cords, trachea and bronchial tree.
Mar 13, 1996 - Effects of fluticasone propionate on arachidonic acidmetabolites in. BAL-fluid and methacholine dose- response curves in non-smoking.
the long-acting β2-agonist salmeterol (FS) for mainte- nance treatment ... The proportions of episode-free or sick- leave days ... superior to ICS or LABA alone [4-13] or a leukotriene receptor ... ing 12 months and at least one hospital stay due to.
EFFICACY OF THE COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL IN PATIENTS WITH MODERATE PERSISTENT ASTHMA WITHIN A „R EAL - LIFE “ S ETTING * M. Trautmann1, N. Banik1, J. T. Tews1, R. A. Jörres2, D. Nowak2 2 Institute
1 GlaxoSmithKline, Munich, Germany and Outpatient Clinic for Occupational and Environmental Medicine, Ludwig-Maximilians-University, Munich, Germany
Abstract There are only few data on the effectiveness of recommended drug therapies in asthma under “real-life” conditions without targeted intervention. The study aimed at analyzing the efficacy of the fixed combination of the inhaled corticosteroid fluticasone propionate and the long-acting β2-agonist salmeterol (FS) for maintenance treatment of moderate persistent asthma (GINA stage 3) within an observational design, mimicking “real-life” as closely as possible. The fixed combination was compared with other forms of treatment that were in accordance with treatment guidelines (pooled comparison (PC) group). Patients kept a diary during a 12month observation period and routine visits were taken for surveillance. Among 596 patients, 371 patients belonged to the FS and 225 patients to the PC group. The proportion of symptom-free days (SFD) was higher in the FS than PC group (median, 76 vs 67%; p=0.002). Furthermore, the change in asthma control score (p
